Ocular Therapeutix Inc (NASDAQ:OCUL) – Analysts at Cantor Fitzgerald issued their FY2017 EPS estimates for Ocular Therapeutix in a research note issued on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst E. Piros anticipates that the biopharmaceutical company will post earnings per share of ($2.46) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.
Other analysts have also issued research reports about the stock. BTIG Research reiterated a “buy” rating and issued a $13.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 21st. Zacks Investment Research raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Wednesday, March 22nd. Finally, Cowen and Company reissued an “outperform” rating and issued a $60.00 price target on shares of Ocular Therapeutix in a report on Monday, March 13th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $24.19.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/04/21/equities-analysts-set-expectations-for-ocular-therapeutix-incs-fy2017-earnings-ocul-updated-updated.html.
Shares of Ocular Therapeutix (NASDAQ:OCUL) traded up 0.287% during midday trading on Thursday, hitting $8.725. 297,233 shares of the stock traded hands. The firm has a 50-day moving average price of $8.83 and a 200-day moving average price of $8.08. Ocular Therapeutix has a 52 week low of $4.04 and a 52 week high of $14.50. The stock’s market capitalization is $250.90 million.
Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Friday, March 10th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.07. Ocular Therapeutix had a negative return on equity of 56.23% and a negative net margin of 2,346.47%. The company had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.48 million. During the same period in the prior year, the company earned ($0.43) EPS. The firm’s revenue was up 15.9% on a year-over-year basis.
Several institutional investors have recently modified their holdings of the company. Columbus Circle Investors increased its stake in Ocular Therapeutix by 131.4% in the first quarter. Columbus Circle Investors now owns 1,087,605 shares of the biopharmaceutical company’s stock valued at $10,093,000 after buying an additional 617,515 shares during the period. Berson & Corrado Investment Advisors LLC increased its stake in Ocular Therapeutix by 5.8% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 32,805 shares of the biopharmaceutical company’s stock valued at $304,000 after buying an additional 1,785 shares during the period. Teachers Advisors LLC increased its stake in Ocular Therapeutix by 47.7% in the fourth quarter. Teachers Advisors LLC now owns 37,318 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 12,050 shares during the period. Opaleye Management Inc. acquired a new stake in Ocular Therapeutix during the fourth quarter valued at approximately $783,000. Finally, Ellington Management Group LLC increased its stake in shares of Ocular Therapeutix by 25.4% in the fourth quarter. Ellington Management Group LLC now owns 21,200 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 4,300 shares during the last quarter. 66.59% of the stock is currently owned by institutional investors.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocular Therapeutix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc and related companies with MarketBeat.com's FREE daily email newsletter.